Cover Image
Market Research Report

Global Market for Contract Research Organization (CRO) Services

Published by BCC Research Product code 755083
Published Content info 82 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Market for Contract Research Organization (CRO) Services
Published: November 30, 2018 Content info: 82 Pages
Description

Report Highlights:

The global market for CRO's across the clinical trial process should grow from $45.5 billion in 2017 to reach $72.3 billion by 2022 at a compound annual growth rate (CAGR) of 9.7% for the period of 2017-2022.

Clinical (phases I-IV and others) segment of CRO market should grow from $34.7 billion in 2017 to reach $56.1 billion by 2022 at a CAGR of 10.1% for the period of 2017-2022.

Preclinical/pre-human safety and development segment of CRO market should grow from $4.9 billion in 2017 to reach $7.7 billion by 2022 at a CAGR of 9.7% for the period of 2017-2022.

Report Scope:

The Global CRO market is identified in this report along with all major global CRO companies. The total CRO market is broken out globally and by geographic region. Additionally, all major therapeutic areas covered by CROs in the clinical trial process are detailed. The service areas provided by CROs are extensively covered as well. The phases of the clinical trial process and the role provided by CROs are detailed in this report as well.

"This report provides detailed analysis of top CRO companies and their evolving role in the clinical trial process. Faced with rapid development of new therapies, Pharmaceutical companies are increasingly turning to CROs for their services. CRO's expertise within specific therapeutic areas as well as their experience with new and adaptive study design protocols, can reduce costs and study duration. With typical clinical trials costing upwards of $2.5 billion and spanning over a decade from initial testing to Phase IV and post market approval, a thriving market exists to lower these costs and timelines. CROs are expected to continue to play an increasingly role in many facets of the clinical trial process. Oncology, neurology, cardiovascular, metabolism-diabetes, vaccines and other rapidly growing therapeutic areas that have a significant number of drugs in the clinical trial process are detailed in this report.

Strong demand for CRO services is leading to heightened market valuations and correspondingly a plethora of blockbuster Merger and Acquisition deals are taking place. M&A activity has led to a few powerful companies with expertise across many areas of the clinical trial process, although many niche players are still playing a critical role. These emerging trends and changing dynamics within the CRO industry are analyzed in detail in this report."

Report Includes::

  • 19 tables
  • An overview of the global market for contract research organization (CRO) services
  • Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Analyses of the CRO market by services, trial phases, and geographical region
  • Coverage of all major therapeutic areas covered by CROs in the clinical trial process and the types of services they provide
  • Examination of competitive landscape of the market, including mergers and acquisitions, and current pharma CRO contracts
  • Company profiles of key market players, including Charles River Laboratories, Icon Plc, Parexel, Pharmaceutical Product Development and Quintiles
Table of Contents
Product Code: PHM186A

Table of Contents

Chapter 1: Introduction

  • Global CRO Market Trends
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Overview-Clinical Trial Process and CRO Functional Services

  • Clinical Trial Process and Stages
    • Pre-discovery
    • Drug Discovery
    • Preclinical
    • Clinical
    • Phase I
    • Phase II
    • Phase III
    • Post-Marketing Surveillance and Phase IV Studies
  • Regulatory Environment
    • FDA Regulation and Impact
    • The Declaration of Helsinki
    • CDISC Standards
  • Current Market Trends
    • Repurposing Existing Drugs for New Indications
    • Increased Competition through the Resurgence of the Generic Drug Market

Chapter 4: Global Market Overview

  • Global Clinical Trials Shifting toward Asia-Pacific

Chapter 5: Emerging Trends

  • Increasing Complexity of Clinical Trials
  • Small and Mid-sized Biopharma Innovation
  • Small Molecule Versus Biologics
  • Biosimilars
  • Adaptive Trial Design
  • Risk-Based Monitoring
  • Real World Evidence

Chapter 6: Competitive Landscape

  • Functional Service Provider Relationships
  • Offshoring
  • Therapeutic Areas in Drug Development
  • Immuno-Oncology
  • Current Pharma-CRO Contracts
    • Largest Therapeutic Areas Rely on Key CRO Expertise

Chapter 7: Mergers and Acquisitions

  • Recent Merger and Acquisition Activity
    • Quintiles IMS
    • LabCorp, Covance and Chiltern
    • INC Research/Inventiv Health
    • ICON and MAPI
    • Parexel and Pamplona

Chapter 8: Company Profiles

  • Top 10 CROs
    • CHARLES RIVER LABORATORIES
    • CONCORD BIOSCIENCES
    • ICON PLC
    • INC RESEARCH/INVENTIVE HEALTH
    • LABCORP/COVANCE
    • PAREXEL
    • PHARMACEUTICAL PRODUCT DEVELOPMENT
    • PRA HEALTH SERVICES
    • QUINTILES
    • WUXI APPTEC

List of Tables

  • Summary Table: Global CRO Market Across the Clinical Trial Process, by Functional Service, Through 2022
    • Table 1: Global CRO Market, by Therapeutic Area, Through 2022
    • Table 2: Likelihood of Approval, by Major Disease Area/Phase
    • Table 3: Clinical Phase Description
    • Table 4: New Drug Approvals: New Drugs Entering the Market at an Increasing Pace Until Last Year, 2006-2017
    • Table 5: Global CRO Market, by Functional Services, Through 2022
    • Table 6: Increasing Complexity of Clinical Trials, by Design Characteristics in a Typical Clinical Study, 2002-2012
    • Table 7: Small Molecule and Biologics FDA Drug Approvals, 2010-2016
    • Table 8: Global CRO Market for FDA-Approved Small Molecule and Biologics Drugs, Through 2022
    • Table 9: Global CRO Market, by Therapeutic Area, Through 2022
    • Table 10: Key Players in Therapeutic Areas
    • Table 11: Pharma and CRO Partnership Alliances
    • Table 12: Surging CRO Deal Values, 2011-2017
    • Table 13: Pharma M&A and Capital Raising Deal Values Increasing Value of Deals, 2010-2016
    • Table 14: M&A Activity Among Pharma/CROs: Recent M&A Deals in Pharma Outsourcing Sector
    • Table 15: Deal Types in CRO Sector: Improving Capital Markets Leading to More IPOs
    • Table 16: Service Offerings, by Major CRO
    • Table 17: Quintiles' Explosive Growth via Acquisitions, Through 2016
    • Table 18: Quintiles Key Financial and Synergistic Milestones During the Past Five Years

List of Figures

  • Summary Figure: Global CRO Market Across the Clinical Trial Process, by Functional Service, 2016-2022
    • Figure 1: Clinical Pipeline, by Development Phase, 2007-2016
    • Figure 2: Clinical Trial Outsourcing Share, by Functional Service, 2016
    • Figure 3: Drug Approval Timeline
    • Figure 4: Generic Drug Approvals and Filings in the U.S.,2015-2017
    • Figure 5: Average Cost for an Approved Drug, 1970-2010
    • Figure 6: Global CRO Market Size and Growth, 2015-2022
    • Figure 7: Pharma R&D Spending Continues at a Steady Pace, 2006-2022
    • Figure 8: Strong Prescription Drug Sales, 2014-2022
    • Figure 9: CRO are Penetrating Further into R&D Budgets, 2012-2017
    • Figure 10: Global CRO Functional Service Areas Market Share, by Type, 2016
    • Figure 11: Global CRO Clinical Trial Market Share, by Phase, 2016
    • Figure 12: Global CRO Competitor Market Share, by Company, 2017
    • Figure 13: Leading CROs' Preclinical CRO Market Share, by Company, 2017
    • Figure 14: Leading CROs' Clinical Market Share, by Company, 2017
    • Figure 15: Therapeutic Clinical Pipeline Share, by Therapeutic Area, 2017
    • Figure 16: Expanding Value of Outsourcing Deals Involving CROs, 2007-2017
Back to Top